MRUS NASDAQ
Merus N.V.
1W: -7.1%
1M: -6.2%
3M: -4.4%
1Y: +113.9%
3Y: +513.5%
5Y: +390.2%
$90.00
Last traded 2025-12-31 — delisted
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
#51
of 1064
Biotechnology
Technical Signal Map
0 Bullish
1 Neutral
6 Bearish
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| MRUS Merus N.V. | $6.8B | -18.4 | -51.1 | -211.4 | -786.2 | 61.3 | 3 | N/A | 113.9 |
| ONWD.BR Onward Medical N.V. | $120M | -3.1 | -186.0 | -1532.5 | -588.1 | 827.7 | 6 | LEAN BEAR | -50.6 |
| NAMS NewAmsterdam Pharma Company N.V. | $2.8B | -10.6 | -36.8 | 8216.2 | -1732.9 | -88.9 | 2 | BEARISH | -21.0 |
| PRQR ProQR Therapeutics N.V. | $170M | -3.7 | -57.9 | 139.7 | -99.6 | 12.7 | 2 | BEARISH | -24.1 |
| ARGX argenx SE | $58B | 33.3 | 47.3 | 76.3 | 29.8 | 242.1 | 5 | BEARISH | 19.8 |
| QURE uniQure N.V. | $1.6B | -5.8 | -157.6 | 37.9 | -1387.8 | 30.2 | 4 | BEARISH | -57.3 |
| PHARM.AS Pharming Group N.V. | $780M | 66.6 | 3.8 | 3.8 | 1.8 | 7.7 | 7 | BEARISH | -30.4 |
| MRUS Merus N.V. | $6.8B | -18.4 | -51.1 | -211.4 | -786.2 | 61.3 | 3 | N/A | 113.9 |
| ONWD.BR Onward Medical N.V. | $120M | -3.1 | -186.0 | -1532.5 | -588.1 | 827.7 | 6 | LEAN BEAR | -50.6 |
| NAMS NewAmsterdam Pharma Company N.V. | $2.8B | -10.6 | -36.8 | 8216.2 | -1732.9 | -88.9 | 2 | BEARISH | -21.0 |
| PRQR ProQR Therapeutics N.V. | $170M | -3.7 | -57.9 | 139.7 | -99.6 | 12.7 | 2 | BEARISH | -24.1 |
| ARGX argenx SE | $58B | 33.3 | 47.3 | 76.3 | 29.8 | 242.1 | 5 | BEARISH | 19.8 |
| QURE uniQure N.V. | $1.6B | -5.8 | -157.6 | 37.9 | -1387.8 | 30.2 | 4 | BEARISH | -57.3 |
| PHARM.AS Pharming Group N.V. | $780M | 66.6 | 3.8 | 3.8 | 1.8 | 7.7 | 7 | BEARISH | -30.4 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
MRUS vs Benchmarks
ROIC
Gross Margin
Op Margin
Net Margin
Revenue Growth
P/E Ratio
ROE
Piotroski F